<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163194">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01999296</url>
  </required_header>
  <id_info>
    <org_study_id>Thunderbeat in Laparoscopy</org_study_id>
    <nct_id>NCT01999296</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of the Use of Thunderbeat Vessel Sealing Device in Laparoscopic Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantonal Hosptal, Baselland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hosptal, Baselland</source>
  <oversight_info>
    <authority>Switzerland: Laws and standards</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients undergoing laparoscopic visceral and gynecologic procedures using the combined
      bipolar and ultrasonic vessel sealing and dissection device Thunderbeat are entered in a
      prospective registry. Data will be analysed concerning the safe use of the instrument and
      perioperative blood loss.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Intra- and postoperative device-related complications</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Use of additional vessel sealing devices</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative Blood Loss</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Surgery</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Indication for Laparoscopic Surgery (Any)</condition>
  <arm_group>
    <arm_group_label>Patients undergoing laparoscopic surgery</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Use of Thunderbeat (TM) in laparoscopic surgery</intervention_name>
    <arm_group_label>Patients undergoing laparoscopic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an indication for laparoscopic visceral or gynecologic surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients undergoing laparoscopic visceral or gynecologic surgery

          -  need for a vessel sealing device during surgery

        Exclusion Criteria:

          -  non able to understand informed consent or missing consent

          -  age &lt;18
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kantonsspital Baselland Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel C Steinemann, MD</last_name>
      <email>daniel.steinemann@ksbl.ch</email>
    </contact>
    <contact_backup>
      <last_name>Sebastian Lamm, MD</last_name>
      <email>sebastian.lamm@ksbl.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Sebastian Lamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel C Steinemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Zerz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>November 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hosptal, Baselland</investigator_affiliation>
    <investigator_full_name>Daniel Steinemann, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
